In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%. The trial was testing a 7.2 ...
Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.
Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...
Investopedia on MSN13d
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial ResultsNovo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback